Development and Application of Regenerative Medicine in Inflammatory Bowel Disease
Development and Application of Regenerative Medicine in Inflammatory Bowel Disease
复制标题
再生医学在炎症性肠病中的发展及应用
DOI：
10.1159/000527423
复制
发表时间：
2022
期刊：
影响因子：
3.2
通讯作者：
Shimizu Hiromichi
中科院分区：
文献类型：
--
作者：
Okamoto Ryuichi;Mizutani Tomohiro;Shimizu Hiromichi
背景：炎症性肠病（IBD）以胃肠道其他部位的特发性和慢性炎症为特征。因此，在疾病活动期粘膜组织被破坏，因此需要对受损组织进行自发修复，以恢复肠黏膜的功能和长期稳态。此外，在难治性克罗恩病患者中，大量肠道功能的丧失可导致短肠综合征或可能导致致命的肠衰竭。摘要：粘膜愈合的概念认为，对粘膜炎症的调节和受损粘膜的修复对于IBD患者实现理想的临床结果至关重要。然而，目前的治疗缺乏针对粘膜修复的选择，因此，患者必须依靠自身的内在系统来实现粘膜愈合。为了对抗炎症引起的粘膜损伤，目前正在开发各种生物制剂或基于细胞的治疗方法。在早期发育阶段，已经测试了各种生长因子促进粘膜修复的能力。然而，除了重组胰高血糖素样肽-2 （GLP-2）外，大多数这些因素没有显示出临床益处。相反，基于细胞的治疗正在迅速兴起，使用体细胞干细胞和多能干细胞。在这篇综述中，我们重点介绍了基于因子或基于细胞的再生医学在IBD治疗中的现状。此外，我们还想介绍目前组织工程技术的实例，并对再生医学在IBD中的应用进行展望。
Background:Inflammatory bowel disease (IBD) is characterized by idiopathic and chronic inflammation arising elsewhere within the gastrointestinal tract. Consequently, the mucosal tissue is destroyed during the active phase of the disease, and therefore, spontaneous repair of damaged tissue is required to restore the function and long-term homeostasis of the intestinal mucosa. Also, in patients with refractory Crohn’s disease, loss of massive intestinal function can lead to short bowel syndrome or may lead to fatal intestinal failure.Summary:The concept of mucosal healing shares the idea that both regulation of mucosal inflammation and repair of the damaged mucosa are critical to achieve the ideal clinical outcome in patients with IBD. However, current treatments lack the option of those targeted to mucosal repair, and therefore, patients must achieve mucosal healing depending on their intrinsic system. To counteract inflammation-induced mucosal damage, various biologics or cell-based treatments are currently being developed. In the early developmental phase, various growth factors have been tested for their ability to promote mucosal repair. However, most of these factors did not show clinical benefit, except the recombinant glucagon-like peptide-2 (GLP-2). On the contrary, cell-based treatments are rapidly emerging, using both somatic stem cells and pluripotent stem cells.Key Messages:In this review, we focus on the current state of factor-based or cell-based regenerative medicine in the treatment of IBD. Additionally, we would like to introduce current examples of tissue engineering technologies and provide future prospects for the application of regenerative medicine in IBD.
登录
查看更多内容
影响因子：
3.4
作者：
Eliasson, Johanna;Hvistendahl, Mark K.;Freund, Nanna;Bolognani, Federico;Meyer, Christian;Jeppesen, Palle B.
通讯作者：
Jeppesen, Palle B.
影响因子：
4.9
作者：
通讯作者：
--
影响因子：
23.9
作者：
Galipeau J;Sensébé L
通讯作者：
Sensébé L
影响因子：
35.7
作者：
Naimi, Rahim M.;Hvistendahl, Mark;Bjeppesen, Palle
通讯作者：
Bjeppesen, Palle